Revlimid Related Published Studies
Well-designed clinical trials related to Revlimid (Lenalidomide)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. [2007.11.22]
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. [2007.11.22]
A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. [2007.08.01]
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. [2006.11.15]
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. [2006.09]
Other research related to Revlimid (Lenalidomide)
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. [2008.10.20]
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. [2008.10]
Consolidation Therapy with Bortezomib/Lenalidomide/ Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. [2008.10]
Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. [2008.08.14]
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. [2008.07.31]
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. [2008.07]
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. [2008.07]
Treatment of plasma cell dyscrasias with lenalidomide. [2008.07]
Thalidomide and lenalidomide: Mechanism-based potential drug combinations. [2008.07]
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. [2008.06.01]
Lenalidomide therapy for metastatic renal cell carcinoma. [2008.06]
Lenalidomide in the treatment of multiple myeloma: a review. [2008.06]
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. [2008.06]
Lenalidomide and its role in the management of multiple myeloma. [2008.06]
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. [2008.05.20]
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. [2008.05]
Lenalidomide: a new therapy for multiple myeloma. [2008.05]
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. [2008.04.01]
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. [2008.04.01]
Thromboembolic events with lenalidomide-based therapy for multiple myeloma. [2008.04.01]
Lenalidomide for the treatment of B-cell malignancies. [2008.03.20]
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. [2008.02]
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. [2008.02]
The role of lenalidomide in the management of myelodysplasia with del 5q. [2008.02]
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? [2008.02]
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. [2008.02]
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. [2008.01.01]
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. [2008.01]
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. [2007.12.27]
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. [2007.12.20]
Lenalidomide in multiple myeloma. [2007.12]
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. [2007.12]
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. [2007.12]
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. [2007.10.01]
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. [2007.10]
Lenalidomide in the treatment of multiple myeloma. [2007.09.01]
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. [2007.09]
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. [2007.09]
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. [2007.08]
Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes. [2007.08]
Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma. [2007.07]
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. [2007.06]
Evaluation of the developmental toxicity of lenalidomide in rabbits. [2007.06]
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. [2007.05]
Phase I study of lenalidomide in solid tumors. [2007.05]
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. [2007.04]
Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial. [2007.04]
Lenalidomide in myeloma. [2007.04]
The evolving role of lenalidomide in the treatment of hematologic malignancies. [2007.03]
Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors. [2007.03]
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. [2007.03]
Lenalidomide: the emerging role of a novel targeted agent in malignancies. [2007.02]
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. [2007.01.15]
Risk of thrombosis with lenalidomide and its prevention with aspirin. [2007.01]
Lenalidomide in myelodysplastic syndrome and multiple myeloma. [2007]
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. [2006.12.01]
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. [2006.12.01]
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. [2006.12]
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. [2006.12]
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. [2006.12]
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. [2006.12]
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. [2006.10.05]
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. [2006.10]
Lenalidomide therapy in myelofibrosis with myeloid metaplasia. [2006.08.15]
Lenalidomide in multiple myeloma. [2006.08]
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. [2006.07.15]
Thalidomide and lenalidomide in the treatment of multiple myeloma. [2006.07]
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. [2006.03.01]
Current therapeutic uses of lenalidomide in multiple myeloma. [2006.02]
Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. [2006.02]
Thalidomide and lenalidomide in multiple myeloma. [2006]
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. [2005.12.15]
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. [2005.12.15]
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. [2005.10]
Lenalidomide and thalidomide: mechanisms of action--similarities and differences. [2005.10]
Lenalidomide: patient management strategies. [2005.10]
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. [2005.09.19]
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. [2005.09]
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? [2005.05]
Efficacy of lenalidomide in myelodysplastic syndromes. [2005.02.10]
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. [2005.01]
Other possibly related research studies
Emerging drugs in multiple myeloma. [2007.03]
Myelodysplasia: the good, the fair and the ugly. [2007.03]
The emerging role of novel therapies for the treatment of relapsed myeloma. [2007.02]
Risk-based management of myelodysplastic syndrome. [2007.01]
New drugs 07, part I. [2007.02]
Recent advances in the therapy of renal cancer. [2007.02]
Thalidomide as treatment for digestive tract angiodysplasias. [2006.12]
Immunomodulatory drugs as a therapy for multiple myeloma. [2006.12]
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. [2007.04]
Current status of new drugs for the treatment of patients with multiple myeloma. [2006.12]
Recent advances in the treatment of Multiple Myeloma. [2006.10]
Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. [2006.10]
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. [2006.09]
Pharmacy benefit spending on oral chemotherapy drugs. [2006.09]
[New drugs for myeloma] [2006.09]
|
